Global Genitourinary Partnering 2010 to 2020 provides the full collection of Genitourinary disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
Trends in Genitourinary partnering deals Financial deal terms for headline, upfront and royalty by stage of development Genitourinary partnering agreement structure Genitourinary partnering contract documents Top Genitourinary deals by value Most active Genitourinary dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.
The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Genitourinary dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Genitourinary dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Genitourinary deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genitourinary dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Genitourinary deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Genitourinary partnering deals by specific Genitourinary target announced since 2010. The chapter is organized by specific Genitourinary therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Genitourinary partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Genitourinary partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genitourinary technologies and products.
Report scope Global Genitourinary Partnering 2010 to 2020 is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.
Global Genitourinary Partnering 2010 to 2020 includes: Trends in Genitourinary dealmaking in the biopharma industry since 2010 Analysis of Genitourinary deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Genitourinary deal contract documents Comprehensive access to over 500 Genitourinary deal records The leading Genitourinary deals by value since 2010 Most active Genitourinary dealmakers since 2010
The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie’s disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.
In Global Genitourinary Partnering 2010 to 2020, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Genitourinary Partnering 2010 to 2020 report provides comprehensive access to available deals and contract documents for over 500 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise Genitourinary rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Age Related Macular Degeneration - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2020, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape. Age...
Meningitis - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H1 2020, provides an overview of the Meningitis (Infectious Disease) pipeline landscape. "Meningitis is the inflammation caused by viruses and bacteria...
Toll Like Receptor 4 - Pipeline Review, H1 2020 Summary According to the recently published report ’Toll Like Receptor 4 – Pipeline Review, H1 2020’; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 35 molecules are developed...
Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H1 2020 Summary Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) – Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by...
RAF Proto Oncogene Serine/Threonine Protein Kinase - Pipeline Review, H1 2020 Summary RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 184.108.40.206) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies...
217 pages •
By Asia Market Information & Development Company
• Jul 2020
China’s demand for Prescription Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.